A PYMNTS Company

US/Canada: Botox maker walks away from $50B offer

By  |  May 12, 2014

US-based pharmaceutical giant Allergan has reportedly formally rejected an acquisition bid of nearly $50 billion for the company, proposed by Canadian peer Valeant Pharmaceuticals.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, Allegan shot down the offer because it “substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders.”

    Valeant first announced plans to make a buyout attempt of the US company last month, though noted that it had already faced failures in its acquisition efforts.

    Allergan is the maker of the popular Botox product.

    Full content: DealBook

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.